Mr. Stephen Mulvany:

On PCRS, that figure is the variance at the end of August and is an overrun on its costs. Typically about 70% to 80% of costs in that area are the various drug-related schemes, despite the huge work and savings in the base level costs that the PCRS makes on an ongoing basis. The scheme drives value in the price of drugs and use of generics and biosimilars. We can set it out the figures across the schemes for the Chairman.

Mr. Desmond covered health insurance. At its high point, the acute hospital income from private insurance was about €630 million. That will be less for last year. We have not closed that gap and the service planning process will have to try to do so. However, to be clear, if we have a €100 million gap in that area and we close that, that represents a €100 million cost that must come from elsewhere or money that cannot be invested in something else. That gap has not been closed. That is the Sláintecare recommendation and the implications are more complex and broader than simply finding the €600 million. We will let the group examine that.